$238.58 Million in Sales Expected for Prestige Consumer Healthcare Inc (PBH) This Quarter

Equities research analysts expect Prestige Consumer Healthcare Inc (NYSE:PBH) to announce $238.58 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Prestige Consumer Healthcare’s earnings, with the highest sales estimate coming in at $240.00 million and the lowest estimate coming in at $236.30 million. Prestige Consumer Healthcare reported sales of $258.03 million during the same quarter last year, which indicates a negative year-over-year growth rate of 7.5%. The company is scheduled to announce its next earnings results before the market opens on Thursday, November 1st.

According to Zacks, analysts expect that Prestige Consumer Healthcare will report full year sales of $991.08 million for the current financial year, with estimates ranging from $985.40 million to $994.70 million. For the next fiscal year, analysts anticipate that the business will report sales of $987.13 million, with estimates ranging from $977.50 million to $994.70 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Prestige Consumer Healthcare.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. Prestige Consumer Healthcare had a return on equity of 12.45% and a net margin of 32.76%. The company had revenue of $253.98 million for the quarter, compared to analyst estimates of $253.70 million. During the same period in the previous year, the company posted $0.66 earnings per share. The company’s quarterly revenue was down 1.0% compared to the same quarter last year.



Several analysts recently issued reports on the company. ValuEngine upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “sell” rating in a report on Thursday, October 11th. Zacks Investment Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 10th. Finally, Jefferies Financial Group set a $38.00 target price on Prestige Consumer Healthcare and gave the stock a “hold” rating in a report on Thursday, August 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $71.40.

PBH traded down $0.31 on Thursday, hitting $35.99. 494,487 shares of the company were exchanged, compared to its average volume of 489,815. Prestige Consumer Healthcare has a 12 month low of $27.84 and a 12 month high of $48.24. The firm has a market capitalization of $1.86 billion, a PE ratio of 13.79, a PEG ratio of 1.80 and a beta of 1.09. The company has a debt-to-equity ratio of 1.72, a quick ratio of 1.37 and a current ratio of 2.21.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PBH. Dimensional Fund Advisors LP raised its holdings in Prestige Consumer Healthcare by 37.7% during the second quarter. Dimensional Fund Advisors LP now owns 3,199,714 shares of the company’s stock worth $122,805,000 after acquiring an additional 876,192 shares in the last quarter. FMR LLC raised its holdings in Prestige Consumer Healthcare by 17.2% during the second quarter. FMR LLC now owns 5,880,226 shares of the company’s stock worth $225,683,000 after acquiring an additional 864,847 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its position in Prestige Consumer Healthcare by 47.9% during the second quarter. Fuller & Thaler Asset Management Inc. now owns 1,986,867 shares of the company’s stock worth $76,256,000 after buying an additional 643,312 shares during the last quarter. Dalton Greiner Hartman Maher & Co. acquired a new position in Prestige Consumer Healthcare during the third quarter worth approximately $16,851,000. Finally, BlackRock Inc. increased its position in Prestige Consumer Healthcare by 6.7% during the second quarter. BlackRock Inc. now owns 6,350,034 shares of the company’s stock worth $243,716,000 after buying an additional 400,781 shares during the last quarter.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.

Recommended Story: What is a stock buyback?

Get a free copy of the Zacks research report on Prestige Consumer Healthcare (PBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply